Continued">Continued">Continued">Course Objectives – Children Cancer Hospital Egypt 57357

Course Objectives

The goal of this symposium is to provide healthcare professionals and students with a comprehensive and contemporary review of fundamental principles of cardiovascular diseases and in-depth coverage of selected cardiovascular topics. Hence, allowing them to improve their clinical knowledge and skills related to cardiovascular diseases 
After completion of the program, participants will be able to: 

  • Describe the difference between patients with heart failure with reduced (systolic dysfunction) and preserved ejection fraction (diastolic dysfunction)and how each is diagnosed.
  • Delineate the role that the various neurohomormes  and catecholamines play in the pathophysiology of heart failure.
  • Define stroke volume, CI, CO, EF, preload and afterload.
  • Given a patient with acute decompensated heart failure, provide the appropriate Forrester hemodynamic subset.
  • Apply the documented benefits regarding the efficacy of the vasodilators, ACE inhibitors/ARBs, digoxin, diuretics, beta blockers, aldosterone antagonists, ivabradine, and the angiotensin-receptor/neprilysin inhibitors.
  • Given a patient with systolic (HFrEF) or diastolic (HFpEF) dysfunction, provide recommendations on initiation (drug and dose) for acute pharmacotherapy.
  • Given a patient with systolic (HFrEF) or diastolic (HFpEF), provide specific goals for pharmacotherapy.
  • Assess the role of anticoagulation and statin therapy in patients with chronic heart failure.
  • Given a patient with acute heart failure, provide self-care education regarding their heart failure management.
  • Define Acute Coronary Syndrome, distinguishing between NSTEMI and STEMI from the standpoint of patient presentation, EKG and biomarker changes.
  • Discuss the differences between a stable and unstable plaque.
  • Describe how the TIMI risk score (or similar scores) help define patient risk and help determine treatment strategy.
  • Describe the different forms of coronary revascularization and their different roles.
  • Explain how to instruct a patient to alter their risk factors for ischemic heart disease.
  • Identify which patient populations are most likely to benefit from urgent PCI .
  • Explain the mechanism of action, indication, adverse effects, monitoring parameters for safety and efficacy, and contraindications for each of the following drug classes used in the treatment of UA/NSTEMI and STEMI
  • Based on primary literature Identify which agents reduce mortality in the treatment of UA/NSTE-ACS and STEMI.
  • Select and recommend an appropriate antithrombotic and antiplatelet regimen in the acute management of UA/NSTEMI and STEMI.
  • Identify relative and absolute contraindications for using fibrinolytic therapy in the management of STEMI.
  • Given a patient-specific scenario, design an appropriate acute and chronic drug regimen for the management of UA/NSTEMI and STEMI.
  • Discuss strategies to optimize the use of selected antiarrhythmic agents with respect to dosing, serum drug concentration monitoring, monitoring of adverse affects and drug interactions.
  • Given a patient with acute atrial fibrillation (afib), design a pharmaceutical care plan for the acute treatment of afib for rate and rhythm control as well as anticoagulation strategies,
  • Given a patient with ventricular arrhythmias, design a pharmaceutical care plan to acutely treat the patient.
  • Describe the Classifications of Pulmonary Hypertension (PH).
  • Compare current guidelines for treatment of Pulmonary Arterial Hypertension (PAH).
  • Compare and contrast the available therapies for PAH.
  • Given a patient with PH, develop a specific therapeutic plan to improve both morbidity and mortality.

Contact Us

Program Coordinator

Program Director